New hope for lung scarring: experimental drug ABBV-142 enters Mid-Stage trial

NCT ID NCT07230288

First seen Nov 17, 2025 · Last updated May 13, 2026 · Updated 26 times

Summary

This study tests an experimental drug called ABBV-142 for idiopathic pulmonary fibrosis (IPF), a rare disease that scars the lungs and makes breathing hard. About 165 adults with IPF will receive either ABBV-142 or a placebo for 52 weeks to see if it safely slows lung function decline. The goal is to control the disease and improve quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre d'Investigation Clinique Mauricie /ID# 277949

    RECRUITING

    Trois-Rivières, Quebec, G8T 7A1, Canada

  • China Medical University Hospital /ID# 278039

    RECRUITING

    Taichung, 40447, Taiwan

  • Christie Clinic on University /ID# 277871

    RECRUITING

    Champaign, Illinois, 61820, United States

  • Hannibal Regional Hospital /ID# 277984

    RECRUITING

    Hannibal, Missouri, 63401, United States

  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 278029

    RECRUITING

    Kaohsiung City, 807, Taiwan

  • Sec Clinical Research - East - Dothan - Graceland /ID# 278328

    RECRUITING

    Dothan, Alabama, 36305, United States

Conditions

Explore the condition pages connected to this study.